The Role Of Erythropoietin Hormone And RAAS In Chronic Renal Disease

Abstract

Patients with chronic renal disease (CRD) have altered levels of erythropoietin (EPO), which plays an important role in the process of erythropoiesis. The aim of this study was to measure EPO levels in individuals suffering from (CRD) and compare these levels with a healthy control group, taking into account GFR, and the RAAS system (Renin, angiotensin, Aldosterone). The results show that EPO concentration is significantly lower in EPO patients (7.29±2.67 mIU/ml) than in the control group and its members (11.45±4.07 mIU/ml, p<0.001). EPO levels also decreased significantly in the lower GFR stages of patients with deteriorating renal function. In addition, it is hypothesized that the inverse effect of EPO and the components of the RAAS (renin, ANG II, and ADH) is indicative of regulation. The highlight of this research is how undiagnosed RAAS abnormalities and renal impairment are associated with EPO synthesis deficiency. This adds to the challenge of providing appropriate treatment for patients with CRD.